Sentinel lymph node biopsy and melanoma: 2010 update. Part I

Journal of the American Academy of Dermatology

Volumn 62, Issue 5, 2010, Pages 723-734

  Stebbins, William G ^a   Garibyan, Lilit ^a   Sober, Arthur J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

melanoma; sentinel lymph node biopsy

Indexed keywords

CANCER STAGING; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; HISTOPATHOLOGY; HUMAN; LYMPH NODE DISSECTION; MELANOMA; METASTASIS; PRIORITY JOURNAL; REVIEW; SENTINEL LYMPH NODE BIOPSY; SURGICAL TECHNIQUE;

COST-BENEFIT ANALYSIS; FALSE NEGATIVE REACTIONS; HUMANS; LYMPH NODES; MELANOMA; NEOPLASM STAGING; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 77950585068     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.11.695     Document Type: Review

References (89)

1. Garrison M., and Nathanson L. Prognosis and staging in melanoma. Semin Oncol 23 (1996) 725-733
2. Slingluff Jr. C.L., Stidham K.R., Ricci W.M., Stanley W.E., and Seigler H.F. Surgical management of regional lymph nodes in patients with melanoma. Experience with 4682 patients. Ann Surg 219 (1994) 120-130
3. Perrott R.E., Glass L.F., Reintgen D.S., and Fenske N.A. Reassessing the role of lymphatic mapping and sentinel lymphadenectomy in the management of cutaneous malignant melanoma. J Am Acad Dermatol 49 (2003) 567-588
4. Johnson T.M., Sondak V.K., Bichakjian C.K., and Sabel M.S. The role of sentinel lymph node biopsy for melanoma: evidence assessment. J Am Acad Dermatol 54 (2006) 19-27
5. Halsted W.S. I. The results of radical operations for the cure of carcinoma of the breast. Ann Surg 46 (1907) 1-19
6. Medalie N.S., and Ackerman A.B. Sentinel lymph node biopsy has no benefit for patients with primary cutaneous melanoma metastatic to a lymph node: an assertion based on comprehensive, critical analysis: part II. Am J Dermatopathol 25 (2003) 473-484
7. Grichnik J.M. Hypothesis letter: the reason sentinel and lymph node dissections do not improve melanoma mortality. J Invest Dermatol 129 (2009) 779-781
8. Ohtani O., Ohtani Y., Carati C.J., and Gannon B.J. Fluid and cellular pathways of rat lymph nodes in relation to lymphatic labyrinths and Aquaporin-1 expression. Arch Histol Cytol 66 (2003) 261-272
9. Grichnik J.M. Melanoma, nevogenesis, and stem cell biology. J Invest Dermatol 128 (2008) 2365-2380
10. Murakami T., Cardones A.R., and Hwang S.T. Chemokine receptors and melanoma metastasis. J Dermatol Sci 36 (2004) 71-78
11. Takeuchi H., Fujimoto A., Tanaka M., Yamano T., Hsueh E., and Hoon D.S. CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells. Clin Cancer Res 10 (2004) 2351-2358
12. Pacifico M.D., Grover R., Richman P.I., Daley F.M., Buffa F., and Wilson G.D. Development of a tissue array for primary melanoma with long-term follow-up: discovering melanoma cell adhesion molecule as an important prognostic marker. Plast Reconstr Surg 115 (2005) 367-375
13. Ebrahimnejad A., Streichert T., Nollau P., Horst A.K., Wagener C., Bamberger A.M., et al. CEACAM1 enhances invasion and migration of melanocytic and melanoma cells. Am J Pathol 165 (2004) 1781-1787
14. Breslow A. Tumor thickness, level of invasion and node dissection in stage I cutaneous melanoma. Ann Surg 182 (1975) 572-575
15. Crowley N.J., and Seigler H.F. The role of elective lymph node dissection in the management of patients with thick cutaneous melanoma. Cancer 66 (1990) 2522-2527
16. Snow H. Abstract of a lecture on melanotic cancerous diseases. Lancet (1892) 872-874
17. Balch C.M., Soong S., Ross M.I., Urist M.M., Karakousis C.P., Temple W.J., et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 7 (2000) 87-97
18. Balch C.M., Soong S.J., Bartolucci A.A., Urist M.M., Karakousis C.P., Smith T.J., et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 224 (1996) 255-263
19. Cascinelli N., Morabito A., Santinami M., MacKie R.M., and Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 351 (1998) 793-796
20. Sim F.H., Taylor W.F., Ivins J.C., Pritchard D.J., and Soule E.H. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma. Preliminary results. Cancer 41 (1978) 948-956
21. Veronesi U., Adamus J., Bandiera D.C., Brennhovd I.O., Caceres E., Cascinelli N., et al. Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med 297 (1977) 627-630
22. Veronesi U., Adamus J., Bandiera D.C., Brennhovd O., Caceres E., Cascinelli N., et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 49 (1982) 2420-2430
23. Shivers S.C., Li W., Lin J., Stall A., Stafford M., Messina J., et al. The clinical relevance of molecular staging for melanoma. Recent Results Cancer Res 158 (2001) 187-199
24. Sim F.H., Taylor W.F., Pritchard D.J., and Soule E.H. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc 61 (1986) 697-705
25. Ingvar C., Erichsen C., and Jonsson P.E. Morbidity following prophylactic and therapeutic lymph node dissection for melanoma-a comparison. Tumori 70 (1984) 529-533
26. Urist M.M., Maddox W.A., Kennedy J.E., and Balch C.M. Patient risk factors and surgical morbidity after regional lymphadenectomy in 204 melanoma patients. Cancer 51 (1983) 2152-2156
27. Piepkorn M., Weinstock M.A., and Barnhill R.L. Theoretical and empirical arguments in relation to elective lymph node dissection for melanoma. Arch Dermatol 133 (1997) 995-1002
28. Beitsch P., and Balch C. Operative morbidity and risk factor assessment in melanoma patients undergoing inguinal lymph node dissection. Am J Surg 164 (1992) 462-465
29. Morton DL, Cagle LA, Wong J, Economou JS, Foshag LJ, Wen DR, Cochran AJ. Intraoperative lymphatic mapping and selective lymphadenectomy: technical details of a new procedure or clinical stage I melanoma. Presented at the Annual Meeting of the Society of Surgical Oncology. Washington, DC: 1990.
30. Cochran A.J., Wen D.R., and Herschman H.R. Occult melanoma in lymph nodes detected by antiserum to S-100 protein. Int J Cancer 34 (1984) 159-163
31. Morton D.L., Wen D.R., Wong J.H., Economou J.S., Cagle L.A., Storm F.K., et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127 (1992) 392-399
32. Reintgen D., Cruse C.W., Wells K., Berman C., Fenske N., Glass F., et al. The orderly progression of melanoma nodal metastases. Ann Surg 220 (1994) 759-767
33. Thompson J.F., McCarthy W.H., Bosch C.M., O'Brien C.J., Quinn M.J., Paramaesvaran S., et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 5 (1995) 255-260
34. Alex J.C., Weaver D.L., Fairbank J.T., Rankin B.S., and Krag D.N. Gamma-probe-guided lymph node localization in malignant melanoma. Surg Oncol 2 (1993) 303-308
35. Krag D.N., Meijer S.J., Weaver D.L., Loggie B.W., Harlow S.P., Tanabe K.K., et al. Minimal-access surgery for staging of malignant melanoma. Arch Surg 130 (1995) 654-658
36. Morton D.L., Cochran A.J., Thompson J.F., Elashoff R., Essner R., Glass E.C., et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 242 (2005) 302-311
37. Balch C.M., Buzaid A.C., Soong S.J., Atkins M.B., Cascinelli N., Coit D.G., et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19 (2001) 3635-3648
38. Balch C.M., Soong S.J., Gershenwald J.E., Thompson J.F., Reintgen D.S., Cascinelli N., et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19 (2001) 3622-3634
39. Gershenwald J.E., Colome M.I., Lee J.E., Mansfield P.F., Tseng C., Lee J.J., et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 16 (1998) 2253-2260
40. Morton D.L., and Chan A.D. Current status of intraoperative lymphatic mapping and sentinel lymphadenectomy for melanoma: is it standard of care?. J Am Coll Surg 189 (1999) 214-223
41. Reintgen D.S., Jakub J.W., Pendas S., Swor G., Giuliano R., and Shivers S. The staging of malignant melanoma and the Florida Melanoma Trial. Ann Surg Oncol 11 3 suppl (2004) 186S-191S
42. Cook M.G., Green M.A., Anderson B., Eggermont A.M., Ruiter D.J., Spatz A., et al. The development of optimal pathological assessment of sentinel lymph nodes for melanoma. J Pathol 200 (2003) 314-319
43. Yu L.L., Flotte T.J., Tanabe K.K., Gadd M.A., Cosimi A.B., Sober A.J., et al. Detection of microscopic melanoma metastases in sentinel lymph nodes. Cancer 86 (1999) 617-627
44. Thompson J.F., Stretch J.R., Uren R.F., Ka V.S., and Scolyer R.A. Sentinel node biopsy for melanoma: Where have we been and where are we going?. Ann Surg Oncol 11 3 suppl (2004) 147S-151S
45. van Akkooi A.C., de Wilt J.H., Verhoef C., Schmitz P.I., van Geel A.N., Eggermont A.M., et al. Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative?. Ann Oncol 17 (2006) 1578-1585
46. Roberts A.A., and Cochran A.J. Pathologic analysis of sentinel lymph nodes in melanoma patients: current and future trends. J Surg Oncol 85 (2004) 152-161
47. Gibbs J.F., Huang P.P., Zhang P.J., Kraybill W.G., and Cheney R. Accuracy of pathologic techniques for the diagnosis of metastatic melanoma in sentinel lymph nodes. Ann Surg Oncol 6 (1999) 699-704
48. Cochran A.J., Wen D.R., and Morton D.L. Occult tumor cells in the lymph nodes of patients with pathological stage I malignant melanoma. An immunohistological study. Am J Surg Pathol 12 (1988) 612-618
49. Messina J.L., Glass L.F., Cruse C.W., Berman C., Ku N.K., and Reintgen D.S. Pathologic examination of the sentinel lymph node in malignant melanoma. Am J Surg Pathol 23 (1999) 686-690
50. Cochran A.J. The pathologist's role in sentinel lymph node evaluation. Semin Nucl Med 30 (2000) 11-17
51. Spanknebel K., Coit D.G., Bieligk S.C., Gonen M., Rosai J., and Klimstra D.S. Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis. Am J Surg Pathol 29 (2005) 305-317
52. Wang X., Heller R., VanVoorhis N., Cruse C.W., Glass F., Fenske N., et al. Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg 220 (1994) 768-774
53. Blaheta H.J., Ellwanger U., Schittek B., Sotlar K., MacZey E., Breuninger H., et al. Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. J Invest Dermatol 114 (2000) 637-642
54. Palmieri G., Ascierto P.A., Cossu A., Mozzillo N., Motti M.L., Satriano S.M., et al. Detection of occult melanoma cells in paraffin-embedded histologically negative sentinel lymph nodes using a reverse transcriptase polymerase chain reaction assay. J Clin Oncol 19 (2001) 1437-1443
55. Fontaine D., Parkhill W., Greer W., and Walsh N. Nevus cells in lymph nodes: an association with congenital cutaneous nevi. Am J Dermatopathol 24 (2002) 1-5
56. Gutzmer R., Kaspari M., Brodersen J.P., Mommert S., Völker B., Kapp A., et al. Specificity of tyrosinase and HMB45 PCR in the detection of melanoma metastases in sentinel lymph node biopsies. Histopathology 41 (2002) 510-518
57. Russell-Jones R. The value of reverse transcription-polymerase chain reaction in malignant melanoma. Br J Dermatol 145 (2001) 193-194
58. Taback B., Morton D.L., O'Day S.J., Nguyen D.H., Nakayama T., and Hoon D.S. The clinical utility of multimarker RT-PCR in the detection of occult metastasis in patients with melanoma. Recent Results Cancer Res 158 (2001) 78-92
59. Bostick P.J., Morton D.L., Turner R.R., Huynh K.T., Wang H.J., Elashoff R., et al. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol 17 (1999) 3238-3244
60. Scoggins C.R., Ross M.I., Reintgen D.S., Noyes R.D., Goydos J.S., Beitsch P.D., et al. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol 24 (2006) 2849-2857
61. Mocellin S., Hoon D.S., Pilati P., Rossi C.R., and Nitti D. Sentinel lymph node molecular ultrastaging in patients with melanoma: a systematic review and meta-analysis of prognosis. J Clin Oncol 25 (2007) 1588-1595
62. Vuylsteke R.J., van Leeuwen P.A., Statius Muller M.G., Gietema H.A., Kragt D.R., and Meijer S. Clinical outcome of stage I/II melanoma patients after selective sentinel lymph node dissection: long-term follow-up results. J Clin Oncol 21 (2003) 1057-1065
63. Karim R.Z., Scolyer R.A., Li W., Yee V.S., McKinnon J.G., Li L.X., et al. False negative sentinel lymph node biopsies in melanoma may result from deficiencies in nuclear medicine, surgery, or pathology. Ann Surg 247 (2008) 1003-1010
64. Uren R.F., Howman-Giles R., Thompson J.F., McCarthy W.H., Quinn M.J., Roberts J.M., et al. Interval nodes: the forgotten sentinel nodes in patients with melanoma. Arch Surg 135 (2000) 1168-1172
65. Thompson J.F., and Uren R.F. Teaching points on lymphatic mapping for melanoma from the Sydney Melanoma Unit. Semin Oncol 31 (2004) 349-356
66. Sung J., Li W., Shivers S., and Reintgen D. Molecular analysis in evaluating the sentinel node in malignant melanoma. Ann Surg Oncol 8 9 suppl (2001) 29S-30S
67. Cho K.H., Hashimoto K., Taniguchi Y., Pietruk T., Zarbo R.J., and An T. Immunohistochemical study of melanocytic nevus and malignant melanoma with monoclonal antibodies against S-100 subunits. Cancer 66 (1990) 765-771
68. Li W., Stall A., Shivers S.C., Lin J., Haddad F., Messina J., et al. Clinical relevance of molecular staging for melanoma: comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma. Ann Surg 231 (2000) 795-803
69. Shivers S., Jakub J., Pendas S., and Reintgen D. Molecular staging for patients with malignant melanoma. Expert Rev Anticancer Ther 7 (2007) 1665-1674
70. Takeuchi H., Morton D.L., Kuo C., Turner R.R., Elashoff D., Elashoff R., et al. Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol 22 (2004) 2671-2680
71. van Akkooi A.C., de Wilt J.H., Verhoef C., Graveland W.J., van Geel A.N., Kliffen M., et al. High positive sentinel node identification rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma. Eur J Cancer 42 (2006) 372-380
72. Gershenwald J.E., Thompson W., Mansfield P.F., Lee J.E., Colome M.I., Tseng C.H., et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 17 (1999) 976-983
73. Cochran A.J., Ohsie S.J., and Binder S.W. Pathobiology of the sentinel node. Curr Opin Oncol 20 (2008) 190-195
74. Roka F., Kittler H., Cauzig P., Hoeller C., Hinterhuber G., Wolff K., et al. Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis. Br J Cancer 92 (2005) 662-667
75. Thomas J.M. Concerns relating to the conduct and statistical analysis of the Multicenter Selective Lymphadenectomy Trial (MSLT-1) in patients with melanoma. J Plast Reconstr Aesthet Surg 62 (2009) 442-446
76. Thomas J.M. Prognostic false-positivity of the sentinel node in melanoma. Nat Clin Pract Oncol 5 (2008) 18-23
77. van der Ploeg I.M., Kroon B.B., Antonini N., Valdes Olmos R.A., and Nieweg O.E. Is completion lymph node dissection needed in case of minimal melanoma metastasis in the sentinel node?. Ann Surg 249 (2009) 1003-1007
78. Zitelli J.A. Sentinel lymph node evaluations. Adv Dermatol 23 (2007) 47-60
79. Hueman M.T., and Lange J.R. Sentinel lymph node biopsy in melanoma. Curr Treat Options Oncol 9 (2008) 243-250
80. Thomas J.M. Sentinel lymph node biopsy in malignant melanoma. BMJ 336 (2008) 902-903
81. Rossi C.R., Mocellin S., Scagnet B., Foletto M., Vecchiato A., Pilati P., et al. The role of preoperative ultrasound scan in detecting lymph node metastasis before sentinel node biopsy in melanoma patients. J Surg Oncol 83 (2003) 80-84
82. Voit C., Kron M., Schäfer G., Schoengen A., Audring H., Lukowsky A., et al. Ultrasound-guided fine needle aspiration cytology prior to sentinel lymph node biopsy in melanoma patients. Ann Surg Oncol 13 (2006) 1682-1689
83. Rayatt S.S., Hettiaratchy S.P., Key A., and Powell B.W. Psychosocial benefits of sentinel lymph node biopsy in the management of cutaneous malignant melanoma. Br J Plast Surg 55 (2002) 95-99
84. Rayatt S.S., Hettiaratchy S., Key A., and Powell B.W. Sentinel node biopsy for malignant melanoma. Having this biopsy gives psychological benefits. BMJ 321 (2000) 1285
85. Kilbridge K.L., Weeks J.C., Sober A.J., Haluksa F.G., Slingluff C.L., Atkins M.B., et al. Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol 19 (2001) 812-823
86. Agnese D.M., Abdessalam S.F., Burak Jr. W.E., Magro C.M., Pozderac R.V., and Walker M.J. Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. Surgery 134 (2003) 542-547
87. Otley C.C. Sentinel lymph node biopsy for melanoma-standard of care?. Dermatol Surg 26 (2000) 1067-1069
88. Morton R.L., Howard K., and Thompson J.F. The cost-effectiveness of sentinel node biopsy in patients with intermediate thickness primary cutaneous melanoma. Ann Surg Oncol 16 (2009) 929-940
89. Amersi F., and Morton D.L. The role of sentinel lymph node biopsy in the management of melanoma. Adv Surg 41 (2007) 241-256